EVER FORTUNE AI, a leader in AI medical solutions, is set to achieve significant growth this year. General Manager Yu-Cheng Lee announced on the 14th that after successfully entering the Vietnamese market last year, the company will expand its presence in ASEAN markets, including Thailand and Malaysia, while forming strategic alliances with major medical platforms and AI healthcare companies in Europe and the United States. EVER FORTUNE AI aims to sustain last year’s growth momentum and achieve exponential, triple-digit growth in 2025.
In a recent board meeting, the company approved a stock buyback plan, purchasing 4,000 shares at prices ranging from NT$60 to NT$111 per share. This news boosted the stock price by NT$6.9 on the 14th, closing at NT$76.7. Additionally, NVIDIA founder Jen-hsun Huang’s visit to Taiwan brought attention to AI medical companies, including EVER FORTUNE AI, Medimaging Integrated Solution, and AHEAD Medicine.
As the domestic leader in AI medical products, EVER FORTUNE AI has secured 43 medical device approvals worldwide, including 12 FDA clearances in the U.S., 16 TFDA approvals in Taiwan, and 20 licenses in four ASEAN countries. With robust R&D capabilities, the company achieved significant growth in 2024, with annual revenue reaching NT$345 million—a 270% increase from 2023. Analysts estimate that the company has turned profitable, with earnings per share likely to exceed NT$1 this year.
Yu-Cheng Lee highlighted the company's strategic partnership with the University Medical Shing Mark Hospital in Vietnam. EVER FORTUNE AI is assisting the hospital in implementing 4-6 AI medical software solutions to establish Vietnam’s first smart hospital. Last year, the first product was successfully deployed and tested during a large-scale charitable clinic event. Three additional products will be introduced this year. The company has also secured two major distributors in northern and southern Vietnam, creating substantial business opportunities.
Beyond Vietnam, EVER FORTUNE AI plans to replicate its business model in Thailand and Malaysia, prioritizing these markets along with Singapore as key ASEAN targets.
In Western markets, Lee shared that following the company’s participation in a major North American radiology conference, EVER FORTUNE AI is collaborating with two leading medical platforms to integrate its full suite of AI medical software with healthcare institutions in Europe and the U.S. The company is also pursuing cross-licensing agreements with major AI healthcare firms, facilitating the introduction of EVER FORTUNE AI’s products to international markets while supporting the entry of Western AI medical products into Taiwan.
Resource: 長佳智能 AI 醫療產品強攻東協及歐美 今年營運拚三級跳
